Crawford Bayley, AZB & Partners and Covington Burling advised Mumbai-based Famy Care on the $800m (Rs 4,944 crore) acquisition of its female contraceptives business by the world’s second largest drug maker Mylan.

Mylan was advised by Luthra & Luthra and Cravath Swaine & Moore. Platinum Partners and Debevoise & Plimpton advised Famy’s existing investor AIF Capital.

Famy drafted in both AZB and Crawford Bayley on Indian laws.

Crawford Bayley was led by senior partner Sanjay Asher, principal associate Bhumika Batra and associates Sanskriti Relekar, Anuja Takle, Aparajita Chakraborty and Avanti Kale.

The AZB team was led by partner Shuva Mandal and associate Sayak Maity.

Covington partners Jack Bodner and Ralph C Voltmer also acted for Famy on US laws.

Luthra senior partner Mohit Saraf and partner Sudipta Routh acted for Mylan.

Mylan also instructed Cravath partners Mark I Greene and Minh Van Ngo, with associates Kyle C Harmon and Zara Bari leading on the acquisition.

Platinum partner Ankit Majmudar and Debevoise London partner Geoffrey P Burgess and associate Shashwat Patel and Hong Kong associate Parveet Singh Gandoak acted for AIF which, along with the promoters of Famy Care, will get $50m from Mylan according to the Economic Times.

This is Mylan’s second major deal with an Indian drug maker since its $1.6bn acquisition of part of Strides in 2013, reported Mint, on which Platinum had acted for Mylan alongside DSK Legal and Skadden Arps for the target.